Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
about
Cardiovascular safety of anti-diabetic drugsDiabetic cardiomyopathy: pathophysiology and clinical featuresHeart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.Calcium channel blocker-related periperal edema: can it be resolved?Protective effects of PPARγ agonist in acute nephrotic syndrome.Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Pioglitazone initiation and subsequent hospitalization for congestive heart failure.Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.PPARgamma agonists: safety issues in heart failure.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Diabetes, left ventricular systolic dysfunction, and chronic heart failure.Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?PPARγ and Its Role in Cardiovascular Diseases.A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.Exercise- and resveratrol-mediated alterations in adipose tissue metabolism.Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.Pioglitazone treatment increases survival and prevents body weight loss in tumor-bearing animals: possible anti-cachectic effect.Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats.Combination of a peroxisome proliferator-activated receptor-gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats.Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines.Daily variability in dyspnea, edema and body weight in heart failure patients.Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?Medical management of advanced heart failure
P2860
Q26741082-2BAF74D7-1411-423A-9B8F-56B436C756D0Q30457504-A83A50C2-5D77-48B1-A254-7ED91595EFD4Q33527739-2DF6E4BC-8570-4958-BC08-2330ACFC4398Q34356092-8793C809-CDFF-4B1E-8580-62E17EC4D7E1Q35206315-AEA9BC49-775B-4CCA-9B3B-EEA192A9D177Q35747241-BCF1F137-CC42-46D8-99B8-F1DA587F4579Q35928798-EACFC95B-9787-48F8-9618-3C19453388A6Q36319330-CAB4A33D-94CA-4E01-874C-6EA0BC09E31CQ36320556-419BBA19-5713-4870-AA80-40F280C65164Q36570644-45D57894-E3C3-4ADE-B1DE-1F291CC82427Q36632030-842BC5E7-CA3B-496D-AD24-6264C9EBCF79Q36857537-FE3F0383-4E38-4758-BC18-E07FD82C2E84Q37107490-6A3CB0BF-7618-4AAB-8408-64568C979CC8Q37143034-3D77E8B6-6BC9-443A-8ACF-1259DD74D038Q37390750-E400F159-C641-4533-8DD4-C1E91792B039Q37627571-0E6F790B-9A5C-4B3A-8CC2-D3F82A37E838Q37940541-6F5E63C2-2BFB-456C-92D4-D6EC934DADD2Q38183160-5D7B19B3-5010-4542-B8CE-31BC955D60CFQ38825446-649D44E2-2507-42E8-AA30-6FE687DD5DF3Q38895420-D3A0607C-4C19-4EAD-AE28-286ADF03B3FDQ41843180-BC25B240-3B35-4099-B5C4-51BD03183D6AQ42001779-67472EEB-0617-4743-9D0C-41642FB63E03Q42258153-B915B28F-EB31-4721-B2A0-FCC5DE414465Q45208982-9D19D858-8708-4A70-978E-0B3A7C2DA62EQ46155234-7AAF9F0E-C83F-4140-B511-779411E91F5BQ46161380-35503451-9DA9-4DEC-BEA2-0F0CFD75AB25Q46892581-963B6947-19A0-43F2-BC03-F5951932444AQ47333099-322C9408-5F57-400E-9FD9-4C2E1974281FQ50472209-F3888CE4-E0D8-4614-B2DE-C1CE357CA985Q57243283-B7A4F289-D2B6-4291-9B92-F4B85A8B5844Q57396286-9F761E2E-4A2D-45F4-9831-3AB1E35CDD3C
P2860
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Fluid retention after initiati ...... blished chronic heart failure.
@ast
Fluid retention after initiati ...... blished chronic heart failure.
@en
type
label
Fluid retention after initiati ...... blished chronic heart failure.
@ast
Fluid retention after initiati ...... blished chronic heart failure.
@en
prefLabel
Fluid retention after initiati ...... blished chronic heart failure.
@ast
Fluid retention after initiati ...... blished chronic heart failure.
@en
P2093
P1476
Fluid retention after initiati ...... blished chronic heart failure.
@en
P2093
Byron J Hoogwerf
Gary S Francis
James B Young
W H Wilson Tang
P304
P356
10.1016/S0735-1097(03)00159-1
P407
P577
2003-04-01T00:00:00Z